Scientific Advisory Board

Griff Humphreys

Griff Humphreys is currently principal with Aranmore Pharma Consulting. Prior to that he spent 26 years at Bristol-Myers Squibb Pharmaceutical Company, with the last 12 years leading the Biotransformation Department. He received his graduate training at the University of Virginia in chemistry and completed a post-doctoral fellowship at Vanderbilt University in the Center in Molecular Toxicology.

His interests include the consequences of reactive metabolite formation, development of new analytical methodologies for metabolite detection, reaction phenotyping of CYP and UGT catalyzed biotransformations, predictive metabolism and toxicology models, in vitro-in vivo correlations, and strategies for candidate optimization. He has co-authored over 120 refereed manuscripts and numerous reviews and book chapters.

Griff is a member of the ISSX and the ACS Chemical Toxicology Division (TOXI). He is on the Editorial Advisory Boards of Drug Metabolism and Disposition and serves as reviewer for multiple additional journals. He has served on the Executive Committee of TOXI since 2008 and most recently as Program Chair for the 2013-2014 National meetings. He is currently member of the ISSX Council and was a member of the Meeting Organizing Committee for the 22nd NA ISSX Meeting. He will serve as Meeting Chair for the 2019 Drug Metabolism Gordon Research Conference.

Jane Kenny

Jane Kenny, PhD is currently Associate Director/Principal Scientist at Genentech. Jane received her PhD from the University of Liverpool, UK, under Prof. B. Kevin Park and has over 15 years drug discovery and development experience. She leads in vitro ADME at Genentech which is responsible for clearance, binding and DDI evaluation spanning early discovery to late development. This group also has a focus on computational ADME. Her research interests include DDI, IVIVE, PBPK and predictive ADMET. She is active in the DMPK scientific community and has published over 40 peer-reviewed articles, reviews and book chapters.

Ajay Madan

Ajay Madan, Ph.D., D.A.B.T., has served as Crinetics Pharmaceuticals’ Vice President, Development since May 2016. Previously, from May 2002 to July 2016, Dr. Madan worked at Neurocrine Biosciences, Inc., including as Vice President of Preclinical Development from February 2013 to July 2016, where he was responsible for drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology in support of a number of drug discovery and development programs. Since 2004, Dr. Madan has also taught, and continues to teach, courses at the University of California, San Diego on selecting promising drug candidates and preclinical drug discovery and development. Prior to Neurocrine, from 1994 to 2002, Dr. Madan worked at XenoTech LLC, an in vitro drug research company, including as the Chief Scientific Officer, from 2001 to 2002. Dr. Madan is an author of more than 50 scientific publications, and he has been a diplomate of the American Board of Toxicology since 2005. He holds a B.Pharm. degree from Birla Institute of Technology and a Ph.D. in pharmacology and toxicology from the University of Kansas.

Larry Wienkers

Larry C. Wienkers received his BS in Chemistry and Biology in 1986 and his MS in Chemistry in 1988 from Western Washington University. He then earned his Ph.D. in Medicinal Chemistry from University of Washington in 1993 under the direction of Dr William F. Trager. He did postdoctoral work in the department of Drug Metabolism at the Upjohn Company and subsequently joined the company as a Research Scientist 1995. In 1998, Larry became Director of Drug Metabolism Enabling Technologies at Pharmacia & Upjohn and in 2002 became Executive Director of Pharmacokinetics, Dynamics and Metabolism at Pfizer. In 2004 Larry moved to Amgen and recently retired as Vice President and Global Head of the department of Pharmacokinetics and Drug Metabolism. He an American Association of Pharmaceutical Scientists (AAPS) Fellow with over 80 peer reviewed manuscripts and book chapters. One of Larry's long standing research interests is focused on exploring bioactivation pathways associated with small molecule drug metabolism with particular focus on the prospective application of this information to predict drug-drug interactions in the clinic. To this end, he and collaborators apply a multidisciplinary approach using organic chemistry, biochemistry and biophysical techniques to study cytochrome P450 mechanism based inactivation and the characterization of biotransformation pathways of novel therapeutics.